| Website | pappasventures.com |
| Phone | 919-998-3300 |
| Employees |
At Pappas Ventures, their sole focus is investing in the life sciences – biotechnology, specialty pharmaceuticals, drug delivery, medical devices and related ventures. Their success, however, is not simply a product of investment capital. They bring experience, creativity and passion to each and every partnership. And in so doing, they are bringing promising technologies to commercial application – from concept to commerce.
| Company | Date | Round | Size | Participants |
| CeNeRx BioPharma | 2/12 | Series D | $4.6M | 3 |
| CoLucid Pharmaceuticals | 8/11 | Venture Round | $7.5M | 5 |
| TESARO | 6/11 | Series B | $101M | 5 |
| Ultragenyx Pharmaceutical | 6/11 | Series A | $45M | 4 |
| Milestone Pharmaceuticals | 6/11 | Venture Round | $13M | 3 |
| CardioDx | 5/11 | Venture Round | $60M | 13 |
| Chimerix | 2/11 | Series F | $45M | 8 |
| TyRx Pharma | 12/10 | Venture Round | $20M | 3 |
| Achillion Pharmaceuticals | 8/10 | Venture Round | $50.1M | 4 |
| CeNeRx BioPharma | 8/10 | Series C | $13M | 3 |
| Liquidia Technologies | 7/10 | Series C | $5M | 5 |
| CardioDx | 5/10 | Series D | $34.5M | 8 |
| Syndax Pharmaceuticals | 3/10 | Series A | $9M | 5 |
| Liquidia Technologies | 1/10 | Series C | $20M | 5 |
| Afferent Pharmaceuticals | 12/09 | Series A | $23M | 4 |
| Barosense | 8/09 | Series D | $27M | 7 |
| Biosyntech | 8/09 | Venture Round | $1.4M | 4 |
| BrainCells | 3/08 | Series B | $30M | 6 |
| LEAD Therapeutics | 11/07 | Series A | $17M | 3 |
| FlowCardia | 8/07 | Series C | $30M | 9 |
| Gentis | 6/07 | Series A | $10M | 4 |
| Cequent Pharmaceuticals | 6/07 | Series A | $9M | 4 |